Your browser doesn't support javascript.
loading
The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements.
Cedena, Maria-Teresa; Martin-Clavero, Estela; Wong, Sandy; Shah, Nina; Bahri, Natasha; Alonso, Rafael; Barcenas, Carmen; Valeri, Antonio; Salazar Tabares, Johny; Sanchez-Pina, Jose; Cuellar, Clara; Martin, Thomas; Wolf, Jeffrey; Lahuerta, Juan-Jose; Martinez-Lopez, Joaquin.
Afiliação
  • Cedena MT; Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Martin-Clavero E; Instituto de Investigación Sanitaria imas12, H12O-CNIO Hematological Malignancies Research Group, CIBERONC, Complutense University, Madrid, Spain.
  • Wong S; Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Shah N; Instituto de Investigación Sanitaria imas12, H12O-CNIO Hematological Malignancies Research Group, CIBERONC, Complutense University, Madrid, Spain.
  • Bahri N; Bone Marrow Transplantation and Hematologic Malignancy Unit, Division of Hematology-Oncology, University of California, San Francisco, CA, United States of America.
  • Alonso R; Bone Marrow Transplantation and Hematologic Malignancy Unit, Division of Hematology-Oncology, University of California, San Francisco, CA, United States of America.
  • Barcenas C; Bone Marrow Transplantation and Hematologic Malignancy Unit, Division of Hematology-Oncology, University of California, San Francisco, CA, United States of America.
  • Valeri A; Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Salazar Tabares J; Instituto de Investigación Sanitaria imas12, H12O-CNIO Hematological Malignancies Research Group, CIBERONC, Complutense University, Madrid, Spain.
  • Sanchez-Pina J; Pathology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Cuellar C; Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Martin T; Instituto de Investigación Sanitaria imas12, H12O-CNIO Hematological Malignancies Research Group, CIBERONC, Complutense University, Madrid, Spain.
  • Wolf J; Pathology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Lahuerta JJ; Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Martinez-Lopez J; Instituto de Investigación Sanitaria imas12, H12O-CNIO Hematological Malignancies Research Group, CIBERONC, Complutense University, Madrid, Spain.
PLoS One ; 15(8): e0237155, 2020.
Article em En | MEDLINE | ID: mdl-32866200
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: PLoS One Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mieloma Múltiplo Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: PLoS One Ano de publicação: 2020 Tipo de documento: Article